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Abstract  
The repair of large non-unions in long bones remains a significant clinical problem due to high 
failure rates and limited tissue availability for auto- and allografts.  Many cell-based strategies 
for healing bone defects deliver bone marrow stromal cells to the defect site to take advantage of 
the inherent osteogenic capacity of this cell type.  However, many factors, including donor age 
and ex vivo expansion of the cells, cause bone marrow stromal cells to lose their differentiation 
ability.  To overcome these limitations, we have genetically engineered bone marrow stromal 
cells to constitutively overexpress the osteoblast specific transcription factor Runx2.  In the 
present study, we examined Runx2-modified bone marrow stromal cells, delivered via 
poly(caprolactone) scaffolds loaded with type I collagen meshes, in critically-sized segmental 
defects in rats compared to unmodified cells, cell-free scaffolds and empty defects.  Runx2 
expression in bone marrow stromal cells accelerated healing of critically-sized defects compared 
to unmodified bone marrow stromal cells and defects receiving cell-free treatments.  These 
findings provide an accelerated method for healing large bone defects which may reduce 
recovery time and the need for external fixation of critically-sized defects. 
Page 2 of 43
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
R
un
x2
 o
ve
re
xp
re
ss
io
n 
in
 b
on
e 
m
ar
ro
w
 st
ro
m
al
 c
el
ls 
ac
ce
le
ra
te
s b
on
e 
fo
rm
at
io
n 
in
 c
rit
ic
al
ly
-s
iz
ed
 fe
m
or
al
 d
ef
ec
ts 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
10
.00
25
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
3 
 3
Introduction 
 The repair of large bone defects in humans remains a significant clinical problem 
affecting approximately 600,000 people in the U.S. per year and costing upwards of 5 billion 
dollars annually 1, 2.  Despite successful bone healing with auto- and allografts, which are the 
most common clinical treatments for large non-unions, failure rates for these procedures remain 
unacceptably high.  Autografts contain the appropriate cues for osteogenesis and elicit no 
immunogenicity, but donor site morbidity and pain affect as many as 30% of patients who have 
undergone a bone harvest from the iliac crest 3, 4.  Allografts address some of these sourcing 
issues but are further complicated by an increased risk of infection, poor revascularization and 
remodeling, and a high rate of fracture 5-7.  As an alternative approach for bone repair, cell-based 
regenerative medicine strategies are being developed to address the problems associated with 
current bone grafting procedures 8-11. 
 For successful repair and remodeling of large bone defects, a cell population capable of 
producing and remodeling bone must be present in the defect site.  These cells can either be 
recruited from host tissues or delivered to the defect via surgical intervention.  Bone marrow 
stromal cells (BMSCs) offer an attractive solution to cell sourcing for bone tissue engineering 
because they represent a multipotential cell population that contributes to the early stages of 
fracture healing in bone 12.  Human BMSCs can be isolated from bone marrow and delivered 
directly to a defect site to induce healing 13, 14.  BMSCs have the capability of differentiating into 
osteoblasts, among other cell types of the mesodermal lineage, and they mineralize constructs 
both in vitro and in vivo 15-19.  BMSCs also enhance bone healing in critically-sized orthotopic 
defects in rodents and large animals compared to treatment with a scaffold alone 20-23.  Recently, 
Marcacci et al. have reported successful healing of large bone defects in humans treated with 
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 4
autologous BMSCs seeded on bioceramic scaffolds.  These implantations were initially reported 
in 2001, and a 6-7 year follow-up of each patient demonstrated that complete bone implant 
integration was achieved in all patients as determined by radiography and CT analysis 24, 25. 
 The success of these cell-seeded constructs makes a compelling case for the use of 
autologous BMSCs in treating large bone defects in humans.  However, multiple factors affect 
the differentiation of BMSCs into bone-producing osteoblasts.  For example, in vitro expansion 
of BMSCs, a necessary step to obtain sufficient numbers for implantation, causes 
dedifferentiation and subsequent loss of mineralization capacity 26-28.   Furthermore, the 
mineralization potential and proliferation rate of BMSCs varies widely with individual donors 
and is significantly affected by donor age 29-31.  These complications with BMSC function 
suggest that the treatment of large bone defects with autologous BMSCs may not produce 
effective results for all patients.  A strategy for overcoming these difficulties with BMSCs would 
provide great benefit to clinical bone healing. 
 To address these limitations with BMSCs, extensive work has focused on BMP delivery 
to host cells for the upregulation of osteoblastic differentiation 32-36.  However, low biostability 
and/or diffusion of these soluble factors away from a defect site makes the effective dosage for 
human BMP treatment very high, which in turn makes treatment with BMPs an expensive 
therapy 37.  Furthermore, as a soluble factor, diffusion of BMP away from the delivery site 
decreases the amount of bone formed in an implant and may lead to unregulated signaling in 
remote sites 38.  A recent retrospective study of complications due to spinal fusion in the U.S. 
demonstrated that BMP leads to 50% more complications in cervical spinal fusion compared to 
fusion without BMP 39.  As an alternative osteoinductive factor, we have focused on delivering 
the type 2 runt-related Cbfa1 gene Runx2, which encodes an osteoblast-specific transcription 
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factor that works intracellularly to upregulate a host of bone specific genes, including osteocalcin 
and collagen I 40-42.  Runx2 plays an important role in both bone development and bone 
remodeling/repair 43, 44.  Homozygous deletion of Runx2 in mice causes the formation of a 
completely non-mineralized, cartilaginous skeleton and results in immediate postpartum death 45, 
46.  Mice heterozygous for Runx2 display a pathology similar to that observed in the skeletal 
disease cleidocranial displasia 46, 47.  In fact, the human disease, cleidocranial dysplasia, occurs as 
a result of genetic mutations in Runx2 47-49.  The role of Runx2 as an osteoblastic transcription 
factor in human BMSCs has been demonstrated in vitro via DNA binding assays 50.  Furthermore, 
dominant negative expression of Runx2 after osteoblast differentiation causes skeletal 
abnormalities 44, while ex vivo overexpression of Runx2 in both osteoblastic and non-
osteoblastic cells promotes upregulation of bone-specific genes and subsequent mineralization 42, 
51-53.  Finally, overexpression of Runx2 in BMSCs accelerates osteoblastic differentiation and 
subsequent mineralization both in vitro and in vivo when compared to unmodified BMSCs 54, 55, 
making Runx2 overexpression an attractive option for regulating BMSC function. 
 Recently, our group and others have reported significant healing of critically-sized 
defects in a calvarial defect model treated with BMSCs engineered to overexpress Runx2 40, 56, 57.  
While these findings suggest the potential of Runx2 to promote healing of large non-unions in 
long bones, results obtained from calvarial defect studies do not necessarily translate to healing 
in long bones due to the involvement of the dura mater in healing cranial defects 58.  In the 
present study, we examined the effects of constitutive overexpression of Runx2 in BMSCs 
implanted in critically-sized segmental defects in rat femurs.  This model provides a more 
rigorous test bed than a cranial defect by eliminating contributions to healing from the dura 
mater.  This study is the first to investigate Runx2-modified BMCSs for the treatment of large 
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non-unions in long bones, providing better insight into the use of Runx2 as a cell-based gene 
therapy strategy for future clinical bone defect healing. 
Materials and Methods 
Cell harvest and isolation 
Rat BMSCs were isolated from the hind legs of 7-week-old male Lewis rats (Charles 
River Labs) by commonly used methods 59, 60.   For each independent in vivo experiment 
performed, a separate cell harvest was generated by pooling the femoral and tibial cells from 1 to 
2 rats.  To isolate the cells, rats were euthanized by CO2 inhalation (Georgia Tech IACUC-
approved protocol), and the hind limbs removed, taking care to minimize bleeding and 
subsequent clotting.  Surrounding soft tissue was removed from each bone, and the femurs and 
tibias were soaked in cell culture media consisting of αMEM (Invitrogen) + 10% fetal bovine 
serum (FBS, HyClone) + 1% penicillin/streptomycin (pen/strep, Invitrogen) + 0.3 μg/mL 
fungizone.  The distal end of each bone was removed and the marrow was flushed from the 
diaphysis via centrifugation (2 min, 500g) into a sterile tube.  The marrow pellet was then 
resuspended, and transferred to tissue culture-grade polystyrene (Corning).  Three days after 
harvest, plates were rinsed twice in PBS to remove non-adherent hematopoietic cells, and fresh 
media was added.  Media was changed every 3 days.  When plates were 80-90% confluent, 
passage 0 cells were cryopreserved in 10% dimethylsulfoxide (DMSO) in FBS at -80 oC 
overnight, then transferred to liquid nitrogen for long term storage. 
Scaffold fabrication 
 Medical grade polycaprolactone (PCL) scaffolds were manufactured in 9 mm thick sheets 
by fused deposition modeling (Osteopore International, Singapore).  Scaffolds were reproducibly 
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 7
cut from PCL sheets using dermal biopsy punches 4 mm in diameter (Miltex).  MicroCT analysis 
was used to characterize the structural parameters of the scaffolds (Figure 1A).  For in vivo 
studies, scaffold porosity was 81-85%, average pore size was 890 μm and average rod/strut 
thickness was 310 μm. 
 For all studies, scaffolds were cleaned in 70% ethanol for 30 minutes, rinsed 3 times in 
sterile water to remove ethanol, then soaked in PBS for 10-30 minutes prior to cell seeding.  For 
in vivo studies, an additional step was added prior to scaffold sterilization for endotoxin removal.  
For this step, scaffolds were rinsed in 70% ethanol for 4 days on a shaker plate, and ethanol was 
replaced once daily.  Endotoxin levels were below the United States Food and Drug 
Administration’s recommended 0.5 EU/mL, as determined by the LAL chromogenic assay 
(Cambrex).   
To increase cell retention in PCL scaffolds, collagen meshes were produced within the 
scaffold pores by lyophilizing a collagen solution as previously described 61.  Briefly, a sterile 
solution of 1.5 mg/mL type I collagen (MP Biomedicals) was incubated within sterile PCL 
scaffolds at 37 oC for 30 minutes.  Constructs were then frozen for 1 hour at -80 oC and 
lyophilized overnight to produce a fibrous mesh of collagen within the scaffolds. 
Retroviral transduction 
 The Runx2 type II MASNSLF isoform was expressed via the pTJ66 vector as a single 
bicistronic mRNA sequence encoded by murine cDNA (Figure 1B).  An internal ribosomal entry 
site, located downstream from and adjacent to the Runx2 insert, allowed co-expression of a 
fusion protein of zeocin resistance and enhanced green fluorescent protein (eGFP).  eGFP 
expression was quantified via flow cytometry and used as a measure of Runx2 transduction 
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 8
efficiency 52, 53.  Empty pTJ66 vector, which was missing the Runx2 insert but still encoded the 
fusion protein, was used as an empty vector control. 
 To package Runx2 retrovirus, ΦNX helper cells, stably transfected with the Runx2 
plasmid, were grown to sub-confluency in DMEM + 10% FBS + 1% pen/strep.  Twenty four 
hours before the first viral harvest, media was changed and cells were transferred to a 32 oC 
incubator to minimize heat-induced viral degradation.  To harvest virus, media supernatant was 
collected every 12 hours, filtered at 0.45 μm, snap frozen and stored at -80 oC. 
 To transduce primary BMSCs with Runx2 or empty-vector virus, bone marrow stromal 
cells were expanded to passage 3, then trypsinized and seeded into T-75 flasks at a density of 
5,000 cells/cm2.   One day after seeding into flasks, media was replaced with retrovirus 
supplemented with 0.4 μg/mL polybrene, as previously described 52.  Briefly, flasks were 
incubated with viral media at 32 oC for 15 minutes, then centrifuged at 1200g for 30 minutes.  
Viral media was then replaced with fresh αMEM + 10% FBS + 1% pen/strep + 0.3 μg/mL 
fungizone, and cells were incubated at 37 oC.  After 12 hours, a second transduction was 
performed.  Two days after transduction, cells were trypsinized from flasks and seeded onto 
scaffolds or analyzed for eGFP expression by flow cytometry. 
Cell seeding on scaffolds 
Immediately prior to cell seeding, PCL-collagen scaffolds were pre-wet in PBS, then 
wicked on Kimwipes™ to remove excess fluid.  Unmodified, Runx2-modified and empty-
vector-modified cells (passage 4) were trypsinized and seeded at 500,000 cells per scaffold in 50 
μL of media (25 μL per side).  Scaffolds were placed in scaffold holders inside 24 well plates 
and incubated at 37oC to allow cell attachment to the scaffolds.  After 30 minutes of incubation, 
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 9
2 mL of media were added to each well for complete submersion of each scaffold.  Media was 
changed every 3 days. 
To ensure equal cell numbers were seeded onto all scaffolds, unmodified BMSCs were 
seeded onto PCL-collagen scaffolds, as described above, in three separate batches (n=4 scaffolds 
for each batch).  Three days after cell seeding, DNA content on each batch of scaffolds was 
analyzed via Picogreen staining (Quant-iTTM Picogreen® dsDNA Assay Kit – Molecular Probes) 
as previously described 62, 63.  Briefly, constructs were rinsed in PBS, then frozen at -80 oC.  
Thawed samples were dried in a Savant DNA120 SpeedVac Concentrator (Thermo Electron 
Corporation), and digested in 700 μg/mL Proteinase K (Promega) for 48 hours in a 45 oC water 
bath.  Picogreen staining was used to quantify average DNA content/cell numbers on each batch 
of scaffolds.  No differences in cell number were observed among groups (data not shown), 
confirming that cell seeding was reproducible across multiple batches. 
Flow cytometry for transduction efficiency 
For each in vivo study performed, a sample population of cells was harvested and 
analyzed for transduction efficiency.  Briefly, 3 days after Runx2 or empty-vector transduction, 
cells were trypsinized (0.05% trypsin/EDTA – Invitrogen) and resuspended in PBS with 10% 
FBS.  Cell suspensions were centrifuged for 5 minutes at 200-300g, resuspended in PBS and 
then passed through a 40 μm filter (BD Falcon).  eGFP fluorescence was measured on a flow 
cytometer (Becton Dickinson, BD LSR II), and 10,000 events were measured for each sample.  
Data analysis was performed using WinMDI v.2.8.  
Live/Dead staining 
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Cell viability on PCL scaffolds was assessed using the Live/Dead kit (Invitrogen).  
Unmodified and Runx2 modified cells were seeded onto PCL scaffolds with and without 
collagen meshes.  Three days after seeding, constructs were rinsed 3 times in PBS, stained with 4 
μM calcein and 4 μM ethidium homodimer in PBS for 45 minutes at room temperature.  After 
staining, constructs were rinsed 3 times in PBS, and imaged on a confocal microscope (Zeiss 
LSM 510 NLO).  LSM 5 Image Browser was used to stack groups of 2-dimensional image slices. 
Segmental defect surgery 
 Femoral defects were created bilaterally as previously described 64.  Briefly, 13- to 15-
week old female Lewis rats were anesthetized using isoflurane, and the hind limbs were shaved 
and swabbed with cycloheximide and alcohol to prepare the skin for incision.  An anterior 
incision was made from the hip to the knee to allow blunt separation of the quadriceps muscles, 
exposing the femur.  Before the defect was created, a modular fixation device was attached to the 
bone for mechanical support.  The device consisted of two stainless steel plates affixed directly 
to the bone via screws and one polysulfone plate, which spanned the defect and was attached to 
the stainless steel plates (Figure 1C).  Use of this modular system was advantageous for 
postmortem mechanical testing because the polysulfone plate could be removed before defect 
testing without removing the screws or stainless steel plates from the bone, thus avoiding any 
incidental damage to the repair tissue prior to testing.  Furthermore, use of a polysulfone plate for 
support allowed non-invasive in vivo X-ray analysis of defects due to the low X-ray attenuation 
of polysulfone.  After the fixation device was attached, an 8.0-mm segment of bone, amounting 
to 50.6 ± 1.9 mm3 (as measured by post-mortem microCT analysis, n=8), was removed via bone 
saw.  A scaffold was then press fit into the defect.  Notches in the polysulfone plate, spaced 8.0-
mm apart, ensured each defect was consistently created the same length (Figure 1C).  Muscle 
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was closed around the plate and defect using Vicryl sutures, and the skin was closed using 
sutures and wound clips. 
For in vivo studies, five groups were tested: empty defect control (no scaffold or cells 
were placed in the defect) and PCL-scaffolds seeded with (i) unmodified BMSCs, (ii) Runx2-
modified BMSCs, (iii) empty vector-modified BMSCs or (iv) no cells (cell-free scaffolds).  
These groups are outlined in Table 1. 
 Following surgery, animals were given 3 daily doses of buprenorphine at 0.03 mg/kg for 
2 consecutive days and 3 doses of 0.01 mg/kg on the third day to control pain.  Animals were 
monitored daily for signs of pain and distress, progress of wound closure, regular eating habits 
and normal ambulation.  A small percentage (< 8%) of rats developed infections in or around the 
surgery site, or experienced mechanical failure of the fixation device.  These animals were 
removed from the study and euthanized, and any data collected from these animals was excluded.  
Two weeks post surgery, when skin wounds had completely healed, animals were anesthetized 
with isoflurane and wound clips were removed.  At 4, 8, and 12 weeks post-surgery, animals 
were anesthetized with isoflurane and the hind legs were scanned via radiography and microCT 
as described below.  At 12 weeks post-surgery, animals were euthanized by CO2 inhalation, and 
the femurs, along with surrounding muscle tissue, were harvested for postmortem microCT 
evaluation, histology, FTIR analysis and mechanical testing.  
Radiography and microCT analyses 
 Every 4 weeks following surgery, 2-dimensional X-ray images of each sample were non-
invasively obtained using an MX-20 Specimen Radiography System (Faxitron X-ray 
Corporation) to make gross morphological observations of bone formation in each defect site.   
For X-ray analysis, animals were anesthetized in a gas chamber with 5% isoflurane and 
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maintained under anesthesia using 2% isoflurane flow into a face mask.  Each hind leg of 
anesthetized animals was scanned for 15 s with an X-ray beam energy of 23 kV.  X-ray images 
were blindly assessed for extent of bridging and assigned a bridging score from 0-5, as 
previously described 65. 
 In addition to radiographic imaging, samples were non-invasively analyzed every 4 
weeks post-surgery by microCT using a vivaCT 40 (Scanco Medical) to quantify bone volume in 
each defect site.  Sample sizes for each group and time point were as follows:  empty defect n=5, 
PCL n=7, empty vector n=2, BMSC n=11, Runx2 n=11 (4 weeks); empty defect n=5, PCL n=7, 
empty vector n=2, BMSC n=10, Runx2 n=9 (8 weeks); and empty defect n=5, PCL n=6, empty 
vector n=2, BMSC n=9, Runx2 n=9 (12 weeks).  For microCT, animals were anesthetized in the 
same manner as for radiography and placed in a rodent holder with one leg outstretched for 
scanning.  The defect area in between the stainless steel plates of the fixation device was imaged 
with an X-ray beam energy of 55 kVp and intensity of 109 μA, and the integration time was 200 
ms.  Scanning resolution was 38 μm.  After imaging was complete, noise was reduced from 3-
dimensional reconstructions of each scan by applying a Gaussian filter (sigma=1.2, support=2) 
using the Scanco Medical μCT Evaluation Program.  Images were thresholded at 270 mg 
HA/ccm to isolate mature bone from soft tissue and the polymer scaffold and polysulfone plate.  
Bone volume was quantified using directly computed values. 
Histological analysis 
 One sample from each cell group, with bone volume closest to the 12 week median bone 
volume for that group, was chosen as a representative sample for histological analysis.  
Following euthanasia, these samples were immediately fixed in 10% neutral buffered formalin.  
One day after fixation, soft tissue was removed, and specimens were placed in fresh formalin.  
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Prior to embedding, fixed tissues were scanned ex vivo in formalin via microCT as described 
above to allow matching of histological sections with microCT slices.  After scanning, 
specimens were dehydrated in a series of alcohols, cleared in xylene, and embedded in methyl 
methacrylate.  Ground sections, 50-80 μm thick, were prepared by Wasatch Histo Consultants, 
Inc. (Winnemucca, NV) and stained using Sanderson’s Rapid Bone StainTM and a van Gieson 
counterstain 66.  Stained histological sections were then matched to thresholded microCT scans to 
confirm that microCT analysis was representative of mature bone. 
FTIR spectroscopy 
 Explanted samples for FTIR analysis were wrapped in PBS-soaked gauze and frozen at -
20 oC until use.  One representative sample from each group underwent the analysis.  Upon 
thawing, chips of mineralized tissue were removed from the defect area of each sample using a 
bone cutter.  Care was taken to remove only newly formed tissue in the defect area and no native 
host bone.  Mineral chips were fixed in ethanol, then dried overnight at 50 oC, ground with a 
mortar and pestle, pressed into KBr pellets, and read on a Nexus 470 FT-IR (Thermo Nicolet) 
using 64 scans at 4 cm-1 resolution.  Native bone from age-matched Lewis rat femurs was used as 
a positive control for FTIR bone spectra.  Mineral recovered from the defect region of empty 
defect samples was used a negative control. 
Mechanical testing 
Samples for mechanical testing were explanted and wrapped in PBS-soaked gauze and 
frozen at -20 oC until use. Torsional properties for intact age-matched femora from Lewis rats 
were also measured.  Mechanical testing was performed as previously described 64.  Briefly, 
samples were thawed in room temperature PBS and most of the soft tissue was removed, taking 
care not to mechanically disrupt tissue in the defect site.  The ends of each bone were potted in 
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Wood’s metal up to the polysulfone plate and secured with pins into potting blocks.  Blocks were 
loaded onto an ElectroForce® mechanical testing machine (Elf 3200, Bose) and the polysulfone 
plate was removed just before testing.  Samples were loaded in torsion at a displacement rate of 
3o/s up to 360o.  Maximum torque before failure was recorded for each sample. 
Statistical Analysis 
 Data from two independent studies was pooled, and a mixed model ANOVA was used to 
define experiment and individual animal as sources of error.  This analysis was performed using 
the Hierarchical Linear Mixed Models function in Systat v12, which uses a Satterthwaite 
approximation to account for differences in sample sizes.  For mechanical strength, the Tukey-
Kramer method was used to determine differences between the pooled cell conditions (BMSC 
and Runx2) and empty defects, and the Pearson product-moment correlation coefficient was 
calculated for the correlation analysis.  In addition, ridge regression using the Hoerl-Kennard 
model 67, 68, was used to assess the relationship between torsion, bone volume and bridging score 
instead of the conventional linear multi-variate regression because bone volume and bridging 
score are not orthogonal.  A p-value < 0.05 was considered significant.  
Results 
Runx2 expression and cell viability 
 To measure transduction efficiency of the Runx2 and empty-vector retroviruses, eGFP 
expression was measured via flow cytometry.  Unmodified cells were used as a control 
population, and transduction efficiency of retrovirus-transduced cells was determined using the 
2% of background method 69. Runx2-modified cells showed 40% transduction efficiency as 
measured by eGFP expression compared to control cells (Figure 2A).  Empty vector-transduced 
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cells showed 60% transduction efficiency (data not shown).  These transduction efficiencies are 
in agreement with previous reports 60. 
Cell-seeded PCL scaffolds with and without collagen meshes were analyzed to determine cell 
viability and retention on the scaffolds.  Live/Dead staining of cells on scaffolds 3 days post-
seeding shows that unmodified and Runx2-modified BMSCs are viable on PCL scaffolds both 
with and without collagen meshes.  Scaffolds with collagen meshes promote an even distribution 
of cells throughout the pore volume of the PCL while scaffolds without meshes do not retain 
cells in the pore volume (Figure 2B).  PCL scaffolds with collagen meshes were subsequently 
used for all in vivo studies, and “PCL” hereon refers to PCL with collagen mesh. 
Radiography and microCT analysis 
 Immediately following surgery, animals were monitored several times daily for signs of 
pain or stress, regular eating habits, and normal ambulation.  Within one week following surgery, 
signs of stress were minimal, regular eating had returned and normal ambulation using both hind 
limbs was restored. 
To monitor bone formation in critically-sized defects, animals were anesthetized every 4 
weeks and defects were scanned via X-ray and microCT.  X-ray images show gross 
morphological changes in bone growth at the defect site over time.  Whereas empty defects, PCL 
and BMSC groups showed minimal bone formation, Runx2 showed substantial increases in bone 
growth over time (Figure 3).  Representative X-ray images from each group are shown in Figure 
3A, and the corresponding three-dimensional microCT reconstructions at 12 weeks are shown in 
Figure 3B.  No differences were observed between unmodified BMSC and empty vector groups 
(data not shown). 
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At 4, 8 and 12 weeks post-surgery, bone volume in all defects was quantified via 
microCT.  Negligible bone formation occurred at the ends of host bone in empty defects and 
cell-free PCL-treated defects.  However, bone formation in BMSC and Runx2-BMSC treated 
defects increased over time (Figure 3C).  At 4 and 8 weeks post-surgery, Runx2 defects 
contained significantly more bone than unmodified BMSC defects (p < 0.05, n=8).  However, at 
12 weeks, bone volume in Runx2 defects was not significantly different compared to unmodified 
BMSC defects (p = 0.059) (Figure 3C).  On average, the amount of bone formed in Runx2 
treated defects at 12 weeks was about 50% of the total bone volume removed from the femur 
during surgery.  It should be noted that the PCL scaffold occupies volume within each defect, 
which may contribute to the observed lack of difference between Runx2 and BMSC groups at 12 
weeks.  On the whole, this differential time course of bone formation in BMSC- and Runx2-
treated defects indicates that Runx2-modified BMSCs initially accelerate bone formation in 
critically-sized defects but that the osteogenic capacity of unmodified BMSCs eventually 
produces a similar level of bone as Runx2-modified BMSCs.  
Histological analysis 
 To more fully characterize areas of high attenuation imaged by microCT, a representative 
sample from each cell group was subjected to histological analysis at 12 weeks.  Prior to 
embedding, samples were scanned via microCT and thresholded in the same manner described 
above.  Samples were then stained with Sanderson’s Rapid Bone StainTM, which distinguishes 
areas of mineralized bone from demineralized connective tissue and osteoid, revealing 
mineralized bone tissue in a red/pink color and demineralized osteoid in blue/green 70.  Because 
these samples underwent both Sanderson’s stain and microCT scanning, matching slices from 
histology and microCT were compared.  This analysis shows that areas of high attenuation that 
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were thresholded in microCT and used as a measure of bone volume in Figure 3, directly match 
areas of red/pink staining defined as mineralized bone tissue in the Sanderson’s stain.  Histology 
and CT images for Runx2 are shown in Figure 4.  Histology and CT images for BMSC also 
demonstrated this correlation (data not shown). 
FTIR spectroscopic analysis of repair tissue  
 To determine the chemical composition of bone formed in the defects, tissue taken from 
the defect area of a representative sample from each group was analyzed by FTIR spectroscopy 
(Figure 5).  Spectra from native bone (positive control) contains all peaks expected for biologic 
apatite, including amide peaks for protein at 1700 and 1550 cm-1, a small carbonate peak at 900 
cm-1, a broad phosphate peak for stretching vibrations at 900 – 1200 cm-1, and a phosphate 
doublet for bending vibrations at 525 – 625 cm-1 60, 71, 72.  Cell-loaded samples having either 
unmodified BMSCs or Runx2-modified BMSCs displayed all of these bands (Figure 5), 
indicating that the mineralized tissue in these defects was a biological, carbonate-containing 
hydroxyapatite.  Cell-free PCL scaffolds also displayed most of these bands; however, the CO3 
and PO4 (bending) peaks were less prominent in these cell-free samples as compared to native 
control bone or cell-loaded samples and the PO4 doublet indicative of crystalline apatite was not 
evident.  Finally, empty defect negative controls showed amide peaks and some phosphate 
deposits; however, CO3 peaks and prominent PO4 (stretching) peaks were not present, indicating 
that the tissue deposited in these samples did not have the chemical composition of native bone. 
Mechanical strength of repaired defects is dependent on bridging 
 To assess mechanical functionality of the repair tissue present in critically-sized defects, 
femurs were harvested 12 weeks post-surgery and subjected to postmortem torsional testing.  A 
representative torque-displacement curve for Runx2-engineered cell-treated defects is shown in 
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Figure 6A.  Age matched intact femora demonstrated a maximum torque of 279.5 ± 31.0 N·mm 
(n=8) while maximum torque sustained for BMSC- and Runx2-treated defects was 28.8 ± 18.8 
and 28.3 ± 17.5 N·mm, respectively.    Although microCT revealed differences in bone volume 
between BMSC and Runx2 defects at 4 and 8 weeks, maximum torque sustained at 12 weeks 
was not significantly different between these two groups (Figure 6B).  Stiffness and work to 
failure were calculated as the slope of the linear region (highlighted in Figure 6A) and the area 
beneath the curve up to the maximum torque, respectively.  No significant differences among 
experimental groups were observed for either of these parameters (data not shown).  However, 
pooling of the data for cell-treated groups (Runx2 and BMSC) demonstrated a significant 
enhancement in maximum torque for cell-seeded scaffolds compared to empty defect negative 
controls (Figure 6C).  
We hypothesized that mechanical strength is not only dependent on bone volume but also 
on defect bridging.  Without full attachment (i.e. complete bridging) samples that have large 
bone volumes are expected to sustain low torque loads.  To demonstrate that mechanical strength 
of the defects is not only dependent on bone volume but also on defect bridging, X-ray images 
for all samples were blindly assessed for their extent of bridging and assigned a bridging score 
from 0-5.  Scoring criteria and representative X-ray images for each score are shown in Figure 
7A, where 0 is no bone in the defect and 5 is a fully bridged defect.  Whereas some samples 
contain a large amount of bone in the defect site, high mechanical strength is only present when 
this bone is firmly attached to both the proximal and distal ends of the host bone.  A Pearson 
product-moment correlation analysis shows a positive correlation between bone volume and 
maximum torque (r = 0.54, p = 0.027), and the inclusion of bridging scores in the correlation plot 
shows that samples with higher bridging scores generally have greater mechanical strengths 
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(Figure 7B). In addition, a ridge regression analysis was performed with torsion as the dependent 
variable and bone volume and bridging score as independent variables.  For this analysis, a 
Hoerl-Kennard ridge regression model was used instead of the conventional linear multi-variate 
regression because bone volume and bridging score are not orthogonal 67, 68.  This analysis 
yielded regression fit parameters (constant = 9.88, coefficient for bone volume = 0.46, 
coefficient for bridging score = 3.22, ridge parameter = 0.6) and an adjusted R2 value of 0.41. 
Test of significance indicated that this regression fit accurately describes the experimental data 
(p < 0.020).  Although there are no significant differences in torsional strength between BMSC- 
and Runx2-treated defects, a distribution of bridging scores from each group shows that Runx2-
modified defect scores are shifted towards fully bridged or nearly fully bridged (scores 4 and 5) 
compared to unmodified BMSC scores (Figure 7C).  A Kruskal Wallis ANOVA by ranks 
demonstrates that the bridging score distribution for Runx2-treated defects is statistically 
different compared to that for BMSC-treated defects (p < 0.05). 
Discussion 
 This study examined the effects of Runx2 expression in BMSCs on the repair of 
critically-sized segmental defects in rat femurs.  Compared to scaffolds containing unmodified 
BMSCs, scaffolds alone, or empty defects, bone repair was accelerated in defects treated with 
Runx2-engineered BMSCs.  At both 4 and 8 weeks post-surgery, quantitative microCT analysis 
showed significantly more bone formation in defects treated with Runx2-modified BMSCs 
compared to unmodified BMSCs, indicating accelerated healing due to Runx2 treatment.  At 12 
weeks post-surgery, no differences in bone formation between unmodified and Runx2-modified 
BMSCs were present, probably due to the inherent osteogenic capabilities of this cell type.  At 
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all time points, cell-free and empty defects showed negligible bone formation.  Taken together, 
this study demonstrates that Runx2 accelerates healing of large bone defects in vivo. 
 Runx2 has been described as a molecular switch for osteoblastic differentiation 43, yet 
few studies have examined the potential use of Runx2 in healing critically-sized bone defects.  
Three previous critically-sized orthotopic analyses of Runx2-modified BMSCs have been 
performed, all focusing on calvarial defects 40, 56, 57.  Although the cranial defect model provides 
relevant information regarding the healing of craniofacial defects, conflicting evidence regarding 
the role of periosteum, dura mater, and surrounding healthy bone tissue in cranial defect healing 
makes separation of host response from treatment effect difficult in a cranial model 58.  In 
particular, dura mater has been shown to have a significant effect on cranial defect healing 73.  To 
our knowledge, no other study to date has examined the use of Runx2 as a gene therapy strategy 
for the healing of critically-sized segmental defects in long bones.  The present study examined 
Runx2 treatment in a segmental defect model, where contributions from the dura mater are not 
present, making this a more rigorous test bed for the healing of large bone defects. 
 In addition to differences in anatomical location between this study and other orthotopic 
studies of Runx2, factors such as species, time points, and scaffold types also varied between the 
studies.  Zheng et al. implanted adenovirally transduced Runx2-BMSCs on collagen sponges for 
4 weeks in BALB/c mice.  Using manual segmentation of radiographic images, they found 
significantly more bone in defects treated with Runx2-transduced cells over unmodified cells, 
cell-free scaffolds and empty defects 56.  Zhao et al. used adenoviral transduction to deliver 
Runx2 and LacZ (control) to BMSCs.  Cells were implanted on gelatin sponges for 7 weeks in 
C57BL6 mice, and CT quantification showed more bone in defects treated with Runx2 over 
LacZ.  However, no cell-free or empty defect controls were included in this study 57.  Our group 
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has also previously reported on Runx2 treatment of cranial defects.  We have investigated 
BMSCs retrovirally tranduced with Runx2 and implanted on PCL scaffolds for 4 weeks in the rat 
calvarium.  MicroCT analysis showed more bone in Runx2 treated defects, compared to 
unmodified controls and empty defects, following a 21 day pre-culture period.  However, due to 
the open pore structure of our PCL scaffolds, cell-free scaffolds performed as well as Runx2-
engineered cell-loaded scaffolds in this study 40.  Given these differences, all 3 previous 
orthotopic studies comparing Runx2 transduced BMSCs to unmodified or LacZ transduced 
BMSCs showed a significant increase in bone formation due to Runx2 treatment, in agreement 
with the present study. 
 Although Runx2-modified BMSCs accelerated bone repair in critically-sized defects in 
this study, unmodified BMSCs eventually produced equivalent amounts of bone, pointing to the 
inherent ability of BMSCs to mineralize bone defects.  Many studies have demonstrated 
successful healing of bone defects using unmodified BMSCs in both pre-clinical trials 20-22, and 
recently, a pilot study of the implantation of autologous human BMSCs for repair of large bone 
defects in humans was reported by Marcacci et al. 2007.  In this study, 4 patients presented with 
large bone diaphysis defects, for which previous treatment with conventional surgical therapies 
had failed.  Each patient underwent a BMSC harvest from the iliac crest, and the isolated cells 
were then cultured and seeded onto hydroxyapatite scaffolds custom made to fit the size and 
shape of the defects.  For patients 1, 2, and 4, complete consolidation between the implant and 
host bone was radiographically evident between 5-7 months post-surgery, at which time external 
fixation devices were removed.  For these patients, limb function was gradually regained within 
8 months post-surgery.  For patient 3, whose injury was more complex and involved the elbow 
joint, a custom made cast was fitted over the defect after removal of the Ilizarov apparatus at 8 
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months post-surgery.  This patient recovered limb function after 16-24 months post-surgery.  For 
all patients, a 6-7 year follow-up revealed that stable bone-implant integration was maintained 24.  
The success of this study makes treatment with autologous BMSCs an attractive option for 
patients with large bone defects.  However, a reduction in the time needed for external fixation is 
desirable, making the accelerated healing strategy presented in the current study relevant for 
clinical application. 
 The success of unmodified BMSCs for healing critically-sized defects in other pre-
clinical studies may largely depend on the scaffold type used to deliver the cells.  For example, 
all of the aforementioned studies which demonstrate successful healing (i.e. complete bridging) 
of segmental defects when treated with unmodified BMSCs employed the use of a 
hydroxyapatite scaffold to deliver the cells to the defect site.  The osteoconductive properties of 
hydroxyapatite have been reviewed elsewhere 74.  In brief, calcium phosphate ceramics 
demonstrate bioactivity and osteoconductivity leading to rapid and strong osseointegration with 
host bone tissue when implanted into an orthotopic site.  In fact, implantation of HA alone 
(without cells) has been shown to heal osteotomy defects in human patients 75.  In the present 
study, the use of a polymer scaffold, which is not inherently osteoconductive, in combination 
with the rigorous 8-mm segmental defect test bed, may explain why defects treated with 
unmodified BMSCs were not fully healed after 12 weeks.  This result is in agreement with other 
studies that also show non-union of segmental defects treated with unmodified BMSCs when a 
non-ceramic scaffold is the delivery vehicle 76, 77.  Recent evidence suggests that the modification 
of PCL scaffolds with hydroxyapatite nanoparticles increases the bone forming response of cells 
seeded on the scaffolds 78.  In the present study, the rationale behind including a collagen matrix 
within PCL scaffolds was to increase the therapeutic load of cells delivered the defect site.  It is 
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possible that incorporation of an osteoconductive material into our scaffolds would further 
enhance the cellular response 79.   
 A distinguishing aspect of this study over many reports of segmental defect healing is the 
use of mechanical testing to assess functionality of the defects.  Many studies that report 
successful healing of bone defects rely solely on a combination of X-ray analysis and 
histological evaluation as a measure of defect healing.  However, this approach does not provide 
functional information, which is necessary to fully evaluate the success of a given treatment 
strategy for bone healing 80.  Of the few groups that report mechanical testing analysis, the most 
common test method is torsion 36, 64, 81-84.  The current study demonstrates the importance of 
including mechanical testing analysis to evaluate bone healing because, in this case, the 
significant differences in bone volume measured by microCT did not translate to significant 
differences in torsional strength between Runx2 and BMSC treated defects at 12 weeks post-
implantation.  However, we did observe that samples with greater bridging scores generally had 
greater strength than samples with lower bridging scores.  Longer time points may be necessary 
to fully evaluate the effects of gene- and cell-based therapies for bone repair in this model.  
Finally, the present results argue that functional mechanical evaluation of bone defects should be 
used in conjunction with other methods for complete analysis of both bone mass and bone 
quality. 
 In summary, we have demonstrated accelerated bone healing in critically-sized femoral 
defects due to treatment with Runx2-modified BMSCs delivered on synthetic polymer scaffolds.  
Although Runx2 modification did not enhance defect bridging or biomechanical function after 
12 weeks compared to unmodified BMSCs, this genetic modification strategy specifically 
upregulates osteoblastic differentiation thereby offering an accelerated means of bone formation 
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with the potential to shorten healing time for large bone defects in humans. With further 
development, the use of Runx2 as a gene therapy treatment for large bone defects could become 
a valuable strategy for the acceleration of bone healing, reducing recovery time and the need for 
external fixation. 
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Legends for Tables and Figures 
Table 1.  Outline of experimental groups for in vivo segmental defects. 
 
Figure 1.  Scaffolds, Runx2 plasmid, and femoral fixation plate used for segmental defect surgeries.  (A) Cross-
sectional microCT image of a PCL scaffold.  (B) Diagram of Runx2 plasmid showing internal ribosomal entry site 
(IRES) for eGFP expression.  (C) An explanted femur showing the modular fixation plate attached to the bone via 
stainless steel screws.  Notches in the polysulfone plate (marked with arrows) are spaced 8.0 mm apart ensuring 
each defect is created at the same size. 
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Figure 2.  Runx2-modified BMSCs show high eGFP expression at 3 days post-transduction and are viable on PCL 
scaffolds containing lyophilized collagen mesh.  (A) Flow cytometric detection of eGFP expression in unmodified 
and Runx2-modified BMSCs.  Transduction efficiency of Runx2-modified cells is 40% compared to unmodified 
controls.  (B) Confocal live/dead images of unmodified and Runx2-modified BMSCs on PCL scaffolds with and 
without collagen meshes.  Live cells are shown in green and dead cells in red.  Scale bar is 200 μm.  Cells populate 
the pore volume of the PCL by adhering to collagen meshes lyophilized inside the scaffold. 
 
 
Figure 3.  Runx2-modified BMSCs accelerate bone formation in critically-sized defects. (A) X-ray images of 
femoral defects showing representative images for each group.  (B) MicroCT images showing the same samples 
from (A) at 12 weeks.  (C) Bone volume is significantly greater in Runx2-treated defects compared to BMSC-
treated defects at 4 and 8 weeks (* p < 0.05).  At 12 weeks, bone formation due to unmodified BMSCs is not 
significantly different from Runx2-modified cells (p=0.059), indicating that Runx2-modified cells accelerate healing 
but unmodified cells produce similar levels of bone at late time points.  Error bars represent SEM. 
 
 
Figure 4.  Histological analysis confirms that areas of high attenuation revealed by microCT are bone.  (A) 
Sanderson’s rapid bone stain for a Runx2-modified BMSC sample showing bone in red/orange and soft tissue in 
blue/green. (B) A corresponding 2D microCT slice from the same sample, thresholded to isolate areas of high 
attenuation within the sample.  MicroCT analysis shows high correlation with Sanderson’s bone stain. 
 
 
Figure 5.  FTIR spectra demonstrate that the chemical composition of the repair tissue for cell-treated defects is 
similar to that of native bone.  Bands characteristic of biologic hydroxyapatite, namely a small carbonate peak at 855 
– 890 cm-1, a broad phosphate peak at 900 – 1200 cm-1, and a phosphate doublet at 525 – 625 cm-1, are present in 
Runx2-modified and unmodified BMSC-treated defects, as well as native bone.  Cell-free scaffold spectra contain 
peaks that are shifted compared to native bone, and empty defects do not contain characteristic peaks. 
 
Page 36 of 43
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
R
un
x2
 o
ve
re
xp
re
ss
io
n 
in
 b
on
e 
m
ar
ro
w
 st
ro
m
al
 c
el
ls 
ac
ce
le
ra
te
s b
on
e 
fo
rm
at
io
n 
in
 c
rit
ic
al
ly
-s
iz
ed
 fe
m
or
al
 d
ef
ec
ts 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
10
.00
25
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
37 
 37
 
Figure 6.  Mechanical properties of repaired segmental defects.  (A) Representative torque-displacement curve for 
Runx2-treated defects. The curve was plotted as the 20 degree moving average. (B) Despite differences in bone 
volume between Runx2-treated and BMSC-treated defects, maximum torque is not significantly different.  (Empty 
n=5, PCL n=6, BMSC n=9, Runx2 n=8).  (C) Pooled cell-treated groups (Runx2 and BMSC) have significantly 
greater strength than empty defects (* Different from empty defect, p < 0.05).  Error bars represent SEM. 
 
Figure 7.  Maximum torque is correlated with bone volume and extent of defect bridging.  (A) Bridging score 
criteria and representative X-ray images of bridging scores.  (B) Samples with higher bridging scores (shown in the 
legend) are shifted to the upper right of a bone volume versus maximum torque correlation graph.  (C) The 
distribution of bridging scores for Runx2-treated defects is shifted righted compared to that for BMSC-treated 
defects (p < 0.05). 
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